Hongyi Pharmaceutical

Nanchang Hongyi Pharmaceutical Co., Ltd. was established in November 2002 and is located in Nanchang High-tech Zone. It is a national key high-tech enterprise engaged in drug research and development, production and sales, with a total land area of 23,000 square meters, a building area of 28,000 square meters, and registered capital of 30 million yuan. It has production workshops for chemical synthesis, traditional Chinese medicine pretreatment and extraction, and oral solid preparations (granules, tablets, hard capsules, dropping pills, dry suspensions, and powders for inhalation). A total of 23 new products independently developed in six major categories, including the digestive system, cardiovascular system, nervous system, and respiratory system, have been launched and sold successively. In 2011, it was recognized as a high-tech enterprise of Jiangxi Province and a national key high-tech enterprise, and its leading new product "Dalitong Granules" was rated as a national key new product; in 2012, its new drug for treating cardiovascular and cerebrovascular diseases, "Breviscapine Dropping Pills," was rated as a national key new product, and it was awarded the honorary titles of "Top 20 High-growth Industrial Enterprises" and "Top 20 Industrial Enterprises in Scientific and Technological Innovation" by the Nanchang Municipal People's Government; in 2013, it was recognized as a demonstration enterprise of the National Torch Program and a AAA unit of Jiangxi Province for honoring contracts and keeping promises, its granules and tablets passed the new version of drug GMP certification, and the trademarks "Hongyi" and "Dalitong" used by it were recognized as well-known trademarks of Nanchang City; in 2014, it was rated as a demonstration enterprise of "integration of informatization and industrialization" in Jiangxi Province and an advanced enterprise in cleaner production in Jiangxi Province.